•
CM
CMND
Clearmind Medicine Inc. Common Shares
polygon--
Price Chart
Market Cap
3.96M
Volume
35.81K
52W High
$60.80
52W Low
$1.74
Open
$2.58
Prev Close
$2.64
Day Range
2.50 - 2.65
About Clearmind Medicine Inc. Common Shares
Clearmind Medicine Inc is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements. The company's intellectual portfolio currently consists of four patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Latest News
Clearmind Medicine Announces Receipt of Nasdaq Minimum Bid Price Notification
GlobeNewswire Inc.•Dec 5
Evolving Landscape of Mental Health Segment: Key Market Insights of the Latest Published Substance Use Disorders Report — Alcohol Use Disorder, Cocaine Use Disorder, Opioid Use Disorder, and Cannabis Use Disorder | DelveInsight
GlobeNewswire Inc.•Apr 28
SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders
GlobeNewswire Inc.•Apr 25
Clearmind Medicine Files International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders
GlobeNewswire Inc.•Apr 25
Clearmind Medicine Granted Patent for Binge Behavior Treatment by the Macau International Intellectual Property Office
GlobeNewswire Inc.•Jan 2
Clearmind Medicine Looks to Move Forward with its Novel Psychedelic MEAI- Based Alcohol Substitute
GlobeNewswire Inc.•Dec 26
Clearmind Medicine Receives IRB Approval for its FDA-Regulated Clinical Trial
GlobeNewswire Inc.•Dec 24
Alcohol Use Disorder Market Set for Remarkable Growth During the Study Period (2020–2034) | DelveInsight
GlobeNewswire Inc.•Dec 11